Innocutis Introduces Dexter the Dystrophic Nail to Educate the Public on Nail Dystrophy and How Nuvail Can Help Treat This Common Problem

CHARLESTON, S.C., April 16, 2014 /PRNewswire/ -- Innocutis, a specialty pharmaceutical company in Dermatologic and Podiatric specialties, is pleased to announce that Nuvail [poly-ureaurethane, 16%] is currently the #1 Prescribed Brand for Nail Dystrophy in both dermatology and podiatry. Nail Dystrophy affects a vast portion of the U.S. population and the medical community has had limited treatment options to effectively address this growing problem.

Photo - http://photos.prnewswire.com/prnh/20140415/73345

Photo - http://photos.prnewswire.com/prnh/20140415/73344 

An animated social media campaign has been launched to educate on the prevalence of nail dystrophy and NUVAIL as a viable treatment option. The antagonist of healthy nails in this fun, light-hearted, social media campaign is Dexter, the dystrophic nail. Who or what is Dexter? Dexter epitomizes nail dystrophy by representing the splitting, fragile and weak nail associated with dystrophic nails that many patients experience. Innocutis hopes to educate the general public on the various forms of nail dystrophy; most commonly being mycotic (fungal), psoriatic and brittle nail syndrome (affecting as much as 20% of US population). 

Nuvail addresses the signs and symptoms of nail dystrophy by protecting and fortifying the nail plate.   Nuvail is formulated to mechanically support the damaged nail plate using a proprietary polymer blend that creates a strong adhesion to the nail surface. Nuvail's patented polymer creates a breathable barrier allowing for oxygen transfer to the germinal matrix while blocking water absorption; therefore, preventing the wet-dry cycle that commonly leads to damaged nails. 

Daily application of Nuvail also protects the nail from harm caused by work activity such as direct abrasion, friction and over exposure to water or chemicals. The clinical benefits of Nuvail have recently been documented in a peer reviewed clinical study published by the Journal of Drugs in Dermatology.  

Innocutis hopes to show Dexter, the dystrophic nail doesn't stand a fighting chance.

To meet Dexter, the dystrophic nail and learn how Nuvail can help those that suffer from Dexter's dastardly forms, click on the video linked below.

http://nuvail-rx.com/weak-brittle-nails/

Follow Dexter on Twitter: https://twitter.com/dystrophicnail

Like Dexter on Facebook: https://www.facebook.com/DexterTheDystrophicNail

About Innocutis Holdings, LLC:

Innocutis is a pharmaceutical company specializing in the development and commercialization of therapies focused on medical treatments of dermatological conditions.  We believe our focus on dermatologic conditions sets us apart as a company that understands the growing needs of the dermatology specialty.  Our commitment is to be best-in-class in skin-related therapies, providing clinicians with improved solutions for the management of daily challenges experienced in their practice. 

Contact:
Charles F. Jenkins
VP Sales & Marketing
800-499-4468

Read more news from Innocutis Holdings, LLC.

SOURCE Innocutis Holdings, LLC